A research project involving TODD’s FGF21 variant has been selected for funding under the 2026 Korea Drug Development Fund (KDDF) at the Lead Compound Stage for the development of a treatment for metabolic dysfunction-associated steatohepatitis (MASH).
Over the two-year project period, TODD’s FGF21 variant will be further evaluated through preclinical studies, including non-GLP studies in mice.
Todd Pharm has been selected for the 2024 Small and Medium Enterprise Research Personnel Support Project.
On Tuesday, November 18, 2025, Todd Pharm was awarded the Grand Prize at the “IR Demo Day” hosted by the Ewha Womans University Startup Support Group.This award reflects strong recognition of the company’s innovation, business potential, and growth outlook.Todd Pharm…
TODD Pharm was selected for a 1:1 partnering meeting at the Novo Nordisk Partnering Day, as our innovative FGF21 patent was recognized as a technology of interest by Novo Nordisk